Cypralis Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $448K

  • Investors
  • 2

Cypralis General Information

Description

Developer of small-molecule drugs designed to inhibit cyclophilins for treating acute and chronic degenerative conditions. The company discovers and develops non-immunosuppressive cyclophilin inhibitors through pre-clinical studies, clinical programs, academic collaborations, and partnerships with contract research organizations, focusing on cell stress and inflammatory pathways across conditions such as organ injury and pancreatitis, enabling clinicians and researchers to access drug candidates targeting peptidyl-prolyl isomerases for therapeutic investigation.

Contact Information

Website
www.cypralis.com
Formerly Known As
Selcia Pharma
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • Saint John's Innovation Centre
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Saint John's Innovation Centre
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cypralis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Angel (individual) 18-Jun-2018 $448K Completed Pre-Clinical Trials
4. Grant 18-Sep-2017 Completed Pre-Clinical Trials
3. Grant 01-Mar-2017 Completed Pre-Clinical Trials
2. Grant 01-Oct-2015 $307K Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2012 Completed Pre-Clinical Trials
To view Cypralis’s complete valuation and funding history, request access »

Cypralis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Cypralis’s complete cap table history, request access »

Cypralis Patents

  • 68

    Total Documents Applications and Grants

  • Total Patents Families

  • 34

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Cypralis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4526308-A1 Macrocyclic compounds and uses thereof Pending 19-May-2022
GB-202207348-D0 Macrocyclic compounds and uses thereof Inactive 19-May-2022
GB-202307575-D0 Macrocyclic compounds and uses thereof Active 19-May-2022
GB-2620260-A Macrocyclic compounds and uses thereof Active 19-May-2022
GB-2620260-B Macrocyclic compounds and uses thereof Active 19-May-2022 C07D498/18
To view Cypralis’s complete patent history, request access »

Cypralis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cypralis Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital
Innovate UK Government
To view Cypralis’s complete investors history, request access »

Cypralis Investments (1)

Cypralis’s most recent deal was a Corporate Asset Purchase with Scynexis (Cyclophilin Inhibitor Assets). The deal was made on 13-Jul-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Scynexis (Cyclophilin Inhibitor Assets) 13-Jul-2016 Corporate Asset Purchase Buildings and Property
To view Cypralis’s complete investments history, request access »

Ready to get started?

Request a free trial

Cypralis FAQs

  • When was Cypralis founded?

    Cypralis was founded in 2012.

  • Where is Cypralis headquartered?

    Cypralis is headquartered in Cambridge, United Kingdom.

  • What is the size of Cypralis?

    Cypralis has 2 total employees.

  • What industry is Cypralis in?

    Cypralis’s primary industry is Drug Discovery.

  • Is Cypralis a private or public company?

    Cypralis is a Private company.

  • What is the current valuation of Cypralis?

    The current valuation of Cypralis is .

  • What is Cypralis’s current revenue?

    The current revenue for Cypralis is .

  • How much funding has Cypralis raised over time?

    Cypralis has raised $448K.

  • Who are Cypralis’s investors?

    Alzheimers Drug Discovery Foundation and Innovate UK have invested in Cypralis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process